Low Anterior Resection Syndrome Clinical Trial
Official title:
Prospective Evaluation of Bowel Dysfunction After Rectal Cancer Treatment
NCT number | NCT05020132 |
Other study ID # | LARS |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | November 1, 2015 |
Est. completion date | September 1, 2020 |
Verified date | September 2023 |
Source | Consorci Sanitari de Terrassa |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
Bowel dysfunction after rectal cancer treatment may significantly affect the quality of life. Our study aimed to estimate the incidence and characterize the Low Anterior Resection Syndrome(LARS). We performed a prospective evaluation of patients treated with anterior resection for rectal cancer at two hospitals. Assessment was performed at baseline, after neoadjuvant treatment, and 1, 6 and 12 months after bowel transit reconstruction using the following scores: Bristol scale, LARS score, MSK-BFI, FIQL, EORTC-QLQ30 and a visual analogue scale.
Status | Completed |
Enrollment | 113 |
Est. completion date | September 1, 2020 |
Est. primary completion date | September 30, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria: Patients with anterior resection for rectal adenocarcinoma with curative intention, with or without neoadjuvant chemoradiotherapy, total or partial excision of the mesorectum, colorectal or coloanal anastomosis. Exclusion Criteria: - disseminated disease - surgery with palliative intent - refusal to participate in the study - intellectual difficulty to answer the questionnaires |
Country | Name | City | State |
---|---|---|---|
Spain | Consorci Sanitari de Terrassa | Terrassa | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Consorci Sanitari de Terrassa | Hospital Universitari MútuaTerrassa |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in the LARS score between baseline and 12 months | Change in the LARS score (Low Anterior Resection Score) between baseline and 12 months after bowel transit reconstruction (primary surgery or ileostomy closure). The LARS score is a 5-item scoring system which classifies patients into three severity categories: no LARS (0-20 points), minor LARS (21-29 points), and major LARS (30-42 points). A higher score represents worse bowel function. This score also includes a question about the impact on quality of life. | 12 months | |
Primary | Change in the MSK-BFI between baseline and 12 months (MSK-BFI) | Change in the Memorial Sloan-Kettering Cancer Center Bowel Function Instrument (MSK-BFI) between baseline and 12 months after bowel transit reconstruction (primary surgery or ileostomy closure). The MSK-BFI includes 18 questions with five frequency options ranging from never through to always. A total score and three subscales (frequency, diet, and urgency) can be calculated. A higher score represents better bowel function. | 12 months | |
Primary | Change in the Bristol stool chart between baseline and 12 months | Change in the Bristol stool chart between baseline and 12 months after bowel transit reconstruction (primary surgery or ileostomy closure). The Bristol stool chart shows seven categories of stool. The Bristol score was subclassified into three categories: Bristol 1-2 (hard stools), Bristol 3-4 (normal stools), and Bristol 5-7 (loose or liquid stools). | 12 months | |
Secondary | Change in the Visual Analogue Scale (VAS) between baseline and 12 months | Change in the Visual Analogue Scale (VAS) between baseline and 12 months after bowel transit reconstruction (primary surgery or ileostomy closure). The VAS ranges from 0 (worst bowel function) to 10 (best) | 12 months | |
Secondary | Change in the EORTC QLQ-C30 between baseline and 12 months | Change in the European Organization for Research and Treatment of Cancer Quality oF Life Questionnaire (EORTC QLQ-C30) between baseline and 12 months after bowel transit reconstruction (primary surgery or ileostomy closure). The EORTC QLQ-C30 is a self-administered questionnaire developed to assess the quality of life of patients with cancer. The global QoL scale and 5 functional scales (physical, role, cognitive, emotional, and social functioning) can be calculated. All scales range from 0 to 100. A higher score for the global health status represents a higher quality of life, and a higher score for a functional scale represents a higher / healthy level of functioning. | 12 months | |
Secondary | Change in the Fecal Incontinence Quality of Life (FIQL) between baseline and 12 months | Change in the Fecal Incontinence Quality of Life (FIQL) between baseline and 12 months after bowel transit reconstruction (primary surgery or ileostomy closure). The FIQL score includes 29 items which form four scales: lifestyle, coping/behavior, depression/self-perception, and embarrassment. Scores range from 0 to 4 and a higher value represents a better quality of life. | 12 months | |
Secondary | Correlation of the severity of LARS with the quality of life | Correlation of the severity of LARS (LARS score and MSK-BFI) with the quality of life (EORTC QLQ-C30) | 12 months | |
Secondary | Multivariate analysis of risk factors for LARS | Assessment of independent predictors of the LARS score at the 12-month visit in a multiple linear regression model. Univariate linear regression analysis was initially performed to identify the demographic, clinical and surgical factors associated with the 12-month LARS score. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04087421 -
Comparison of Transanal Irrigation and Glycerol Suppositories in Treatment of Low Anterior Resection Syndrome
|
Phase 3 | |
Recruiting |
NCT03828318 -
Impact of a Patient-Centered Program for Low Anterior Resection Syndrome A Multicenter Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT04040842 -
International Low Anterior Resection Score Evaluation
|
||
Recruiting |
NCT04023448 -
The Effect of Different Reconstruction Methods on Anterior Resection Syndrome
|
N/A | |
Not yet recruiting |
NCT06424522 -
A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients
|
Early Phase 1 | |
Completed |
NCT05605600 -
Translation of the International Consensus Definition of LARS Into a Bowl Dysfunction Severity Scoring Tool (New LARS Score)
|
||
Completed |
NCT05016583 -
Paula Method of Exercises in Patients With LARS Syndrome
|
N/A | |
Active, not recruiting |
NCT05042700 -
The Effect of Melatonin in Patients With Low Anterior Resection Syndrome
|
Phase 2 | |
Recruiting |
NCT04612569 -
Feasibility and Impact of a Prehabilitation and Rehabilitation Program for the Continuity of Care in Severe Low Anterior Resection Syndrome.
|
||
Completed |
NCT04896879 -
Experiences and Needs of Patients, Their Informal Caregiver and Healthcare Professionals Regarding LARS
|
||
Recruiting |
NCT06162143 -
Effect of Gelsectan® in the Treatment of Low Anterior Resection Syndrome
|
||
Withdrawn |
NCT03257332 -
Determining Early Development of Faecal Incontinence and Anorectal Muscle Function After Surgery for Rectal Cancer.
|
||
Completed |
NCT03916549 -
Acupuncture in Low Anterior Resection Syndrome Treatment
|
Phase 1 | |
Completed |
NCT03598231 -
Effectiveness of Sacral Neuromodulation in Low Anterior Resection Syndrome
|
N/A | |
Recruiting |
NCT05420870 -
Effect of Exercise on Bowel Function in Colorectal Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT05319054 -
Pathway of Low Anterior Resection Syndrome Relief After Surgery: a Feasibility Study
|
N/A | |
Completed |
NCT01589471 -
The Value of Botox-A for Management of Low Anterior Resection Syndrome
|
Phase 2 | |
Completed |
NCT03215017 -
Effect of Treatment of Low Anterior Resection Syndrome After Rectal Cancer Surgery
|
N/A | |
Completed |
NCT05129215 -
Development and Validation of The Post-RT LARS Prediction Model (PORTLARS)
|
||
Recruiting |
NCT05682157 -
Paula Method of Exercises in Patients With LARS Syndrome:Randomized Controlled Trial
|
N/A |